Astellas Pharma Inc. Share Price OTC Markets
Stocks
ALPMY
US04623U1025
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.73 USD | -4.79% |
|
+4.89% | +3.31% |
| 13/07 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 11/07 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,94500Cr 2.5TCr 2.17TCr 2.02TCr 1.86TCr 3.51TCr 2,36600Cr 3.57TCr 24TCr 9.35TCr 1,19000Cr 9.41TCr 9.21TCr | P/E 2027 * |
11.5x | P/E 2028 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3,81500Cr 2.42TCr 2.1TCr 1.96TCr 1.8TCr 3.4TCr 2,28800Cr 3.45TCr 23TCr 9.04TCr 1,15100Cr 9.1TCr 8.9TCr | EV / Sales 2027 * |
1.69x | EV / Sales 2028 * | 1.67x |
| Free-Float |
97.66% | Yield 2027 * |
3.65% | Yield 2028 * | 3.77% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -4.79% | ||
| 1 week | +4.89% | ||
| Current month | +2.69% | ||
| 1 month | +2.69% | ||
| 3 months | -3.99% | ||
| 6 months | -0.94% | ||
| Current year | +3.31% |
| 1 week | 13.37 |  | 14.47 |
| 1 month | 13.03 | | 14.47 |
| Current year | 12.82 | | 17.35 |
| 1 year | 10.03 | | 17.35 |
| 3 years | 8.37 | | 17.35 |
| 5 years | 8.37 | | 18.18 |
| 10 years | 8.37 | | 18.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.79% | +4.89% | - | - | 2.57TCr | |
| -0.53% | -3.12% | +51.15% | +150.58% | 1,03000Cr | |
| +0.21% | -1.13% | +53.26% | +46.92% | 62TCr | |
| -2.51% | -2.33% | +32.56% | +66.35% | 45TCr | |
| +0.06% | +1.17% | +36.21% | +31.25% | 35TCr | |
| -0.14% | -0.83% | +33.24% | +40.28% | 30TCr | |
| -0.69% | -0.44% | +9.86% | +14.23% | 27TCr | |
| -7.37% | -4.31% | -5.69% | -41.99% | 23TCr | |
| -0.64% | +3.68% | +27.80% | +62.95% | 21TCr | |
| -0.82% | -0.50% | +13.46% | +69.41% | 16TCr | |
| Average | -1.33% | +4.83% | +27.98% | +48.89% | 40.14TCr | |
| Weighted average by Cap. | -0.45% | +4.87% | +36.61% | +70.85% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,26000Cr 1.43TCr 1.24TCr 1.16TCr 1.06TCr 2.01TCr 1,35500Cr 2.04TCr 14TCr 5.36TCr 68TCr 5.39TCr 5.27TCr | 2,07900Cr 1.32TCr 1.15TCr 1.07TCr 979.63Cr 1.85TCr 1,24700Cr 1.88TCr 12TCr 4.93TCr 63TCr 4.96TCr 4.85TCr |
| Net income | 34TCr 217.3Cr 188.7Cr 175.55Cr 161.4Cr 304.85Cr 21TCr 309.82Cr 2.05TCr 811.8Cr 10TCr 817.21Cr 799.3Cr | 33TCr 209.84Cr 182.22Cr 169.52Cr 155.86Cr 294.38Cr 20TCr 299.18Cr 1.98TCr 783.91Cr 9.98TCr 789.14Cr 771.84Cr |
| Net Debt | -13TCr -83Cr -72Cr -67Cr -61Cr -115.77Cr -7.8TCr -117.65Cr -779.79Cr -308.27Cr -3.93TCr -310.33Cr -303.53Cr | -47TCr -299.63Cr -260.19Cr -242.06Cr -222.55Cr -420.35Cr -28TCr -427.2Cr -2.83TCr -1.12TCr -14TCr -1.13TCr -1.1TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/26/31 | $13.73 | -4.79% | 1,47,959 |
| 30/26/30 | $14.42 | +3.37% | 1,24,999 |
| 29/26/29 | $13.95 | +2.20% | 77,611 |
| 28/26/28 | $13.65 | +1.78% | 1,30,246 |
| 27/26/27 | $13.41 | +1.56% | 1,75,779 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
- ALPMY Stock
Select your edition
All financial news and data tailored to specific country editions
